New treatments for herpes simplex virus infections affecting the eye
Official title: Combating Corneal HSV Infection with Novel Dynasore Analogues
Funded at Medchem Partners, LLC · NIH-11012831 · Data updated 2026-11-12
This study is looking at new treatments for herpes infections that can harm your eyes, using a special compound to help stop the virus from spreading and causing damage, with the hope of giving you better options that are easier on your body.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medchem Partners, LLC NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $178,554 |
| NIH project number | 5R41EY035879-02 |
| Project ID | NIH-11012831 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals over 21 years old who are at risk of or currently experiencing HSV-related ocular infections.
✕Less likely to help
Patients with HSV infections who are under 21 years old may not receive benefit from this research.
What this research studies
This research focuses on developing new therapies to combat herpes simplex virus (HSV) infections that can lead to serious eye damage. The approach involves using novel analogues of a compound called dynasore, which has shown promise in inhibiting various stages of the HSV life cycle. By targeting the virus's ability to infect and spread within the eye, the goal is to reduce inflammation and preserve vision. Patients may benefit from improved treatment options that have fewer side effects compared to current therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for preventing vision loss due to HSV infections.
How similar studies have gone: Previous research has shown that targeting multiple steps in the HSV life cycle can be effective, suggesting this approach has potential for success.
Where this research is happening
-
Medchem Partners, LLC
Lexington, United States Active
Researchers
- Principal investigator: Lazarova, Tsvetelina Ivanonova — Medchem Partners, LLC
- Study coordinator: Lazarova, Tsvetelina Ivanonova
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.